# APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

> **NCT03537482** · EARLY_PHASE1 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** APG-2575

## Key facts

- **NCT ID:** NCT03537482
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-07
- **Primary completion:** 2024-09-15
- **Final completion:** 2025-02-15
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03537482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03537482, "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03537482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*